Wayde M Weston

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials
    Wayde M Weston
    GSK Biologicals, GlaxoSmithKline, King of Prussia, PA 19406, USA
    Vaccine 30:1721-8. 2012
  2. ncbi Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years
    Wayde M Weston
    GlaxoSmithKline Biologicals, 2301 Renaissance Boulevard, RN0220, King of Prussia, PA 19406, USA
    Expert Rev Vaccines 7:1309-20. 2008
  3. ncbi Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults
    Wayde M Weston
    GlaxoSmithKline Biologicals, King of Prussia, PA, USA
    Hum Vaccin 5:858-66. 2009
  4. ncbi Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration
    Wayde M Weston
    GlaxoSmithKline, 2301 Renaissance Boulevard, RN0220, King of Prussia, PA 19406, USA
    Vaccine 29:1017-22. 2011
  5. ncbi Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine
    Wayde Weston
    GlaxoSmithKline, King of Prussia, PA, USA
    Vaccine 29:8483-6. 2011

Collaborators

Detail Information

Publications5

  1. ncbi Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials
    Wayde M Weston
    GSK Biologicals, GlaxoSmithKline, King of Prussia, PA 19406, USA
    Vaccine 30:1721-8. 2012
    ..Pertussis can cause significant morbidity in elderly patients, who can also transmit this disease to infants and young children. There is little data available on the use of acellular pertussis vaccines in recipients ≥65 years of age...
  2. ncbi Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years
    Wayde M Weston
    GlaxoSmithKline Biologicals, 2301 Renaissance Boulevard, RN0220, King of Prussia, PA 19406, USA
    Expert Rev Vaccines 7:1309-20. 2008
    ..Strategies such as the use of combined vaccines can help to maintain high levels of coverage against diphtheria, tetanus, pertussis and poliomyelitis diseases...
  3. ncbi Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults
    Wayde M Weston
    GlaxoSmithKline Biologicals, King of Prussia, PA, USA
    Hum Vaccin 5:858-66. 2009
    ..Reporting of adverse events appeared to be similar between groups. The data support the conclusion that Tdap and TIV vaccines may be co-administered without compromising either the effectiveness or tolerability of either vaccine...
  4. ncbi Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration
    Wayde M Weston
    GlaxoSmithKline, 2301 Renaissance Boulevard, RN0220, King of Prussia, PA 19406, USA
    Vaccine 29:1017-22. 2011
    ..The data provide support for current recommendations for co-administration of Tdap and MCV4 vaccines at the same office visit...
  5. ncbi Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine
    Wayde Weston
    GlaxoSmithKline, King of Prussia, PA, USA
    Vaccine 29:8483-6. 2011
    ..Seroprotection rates for diphtheria and tetanus remained high for both Tdap vaccines (for diphtheria, 96.9% and 97.8% for the Tdap-B and Tdap-A groups, respectively; for tetanus, 98.1% and 99.6%, respectively)...